OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
23
Results
Show all
Save search
Copy query
Show results for
Unknown
(23)
Publication Date
Release Date
2021
(6)
2025
(4)
2023
(4)
2022
(4)
2024
(1)
2020
(1)
2013
(1)
2011
(1)
2010
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
Not available
S-EPMC3158597
|
biostudies-literature
Cite
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.
Not available
S-EPMC3587293
|
biostudies-literature
Cite
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.
Not available
S-EPMC3729659
|
biostudies-literature
Cite
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
Not available
S-EPMC8121538
|
biostudies-literature
Cite
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355
|
biostudies-literature
Cite
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8598213
|
biostudies-literature
Cite
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC11872607
|
biostudies-literature
Cite
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483
|
biostudies-literature
Cite
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC7884931
|
biostudies-literature
Cite
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets